Skip to main content

and
  1. Article

    Open Access

    Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

    To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile, in addition to pelvic radiotherapy, for women with high risk an...

    Prunella Blinman, Linda Mileshkin, Pearly Khaw, Geraldine Goss in British Journal of Cancer (2016)